0001193125-12-340595.txt : 20120807 0001193125-12-340595.hdr.sgml : 20120807 20120807145654 ACCESSION NUMBER: 0001193125-12-340595 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120807 DATE AS OF CHANGE: 20120807 EFFECTIVENESS DATE: 20120807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-06964 FILM NUMBER: 121012923 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 13F-HR 1 d390193d13fhr.txt FORM 13F HOLDINGS REPORT ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: June 30, 2012 Check here if Amendment [ ]; Amendment Number: This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Schaffhausen Switzerland CH-8200 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Pascal Schmucki Title: SIGNING AUTHORITY Phone: 41 (44) 267 67 00 Signature, Place, and Date of Signing: /s/ Pascal Schmucki ----------------------------------------- Schaffhausen, Switzerland, August 3, 2012 Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) ================================================================================ Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 3 Form 13F Information Table Entry Total: 20 Form 13F Information Table Value Total: $ 1,073,529 (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Form 13F File Number Name 1 28-11193 Biotech Focus N.V. 2 28-11191 Biotech Invest N.V. 3 28-11189 Biotech Target N.V. BB BIOTECH AG FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 --------------- -------- --------- --------- ----------------- -------- ----------- -------- ------------------------ TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE --------------- -------- --------- --------- --------- ------ -------- ----------- -------- ---------- ------ ----- Achillion COM 00448Q201 9,792 1,579,340 SH DEFINED 3 1,579,340 NONE NONE Pharmaceuticals Inc Alexion COM 015351109 44,685 450,000 SH DEFINED 2 450,000 NONE NONE Pharmaceuticals Inc Amylin COM 032346108 61,290 2,173,391 SH DEFINED 2 2,173,391 NONE NONE Pharmaceuticals Inc Ariad COM 04033A100 53,408 3,103,331 SH DEFINED 3 3,103,331 NONE NONE Pharmaceuticals Inc Biomarin COM 09061G101 38,612 975,545 SH DEFINED 2 975,545 NONE NONE Pharmaceutical Inc Celgene Corp COM 151020104 174,708 2,723,000 SH DEFINED 2 2,723,000 NONE NONE Dendreon Corp COM 24823Q107 11,281 1,524,500 SH DEFINED 2 1,524,500 NONE NONE Endocyte Inc COM 29269A102 11,060 1,345,493 SH DEFINED 3 1,345,493 NONE NONE Gilead COM 375558103 108,201 2,110,000 SH DEFINED 1 2,110,000 NONE NONE Sciences Inc Halozyme COM 40637H109 45,226 5,104,500 SH DEFINED 3 5,104,500 NONE NONE Therapeutics Inc Human Genome COM 444903108 26,260 2,000,000 SH DEFINED 2 2,000,000 NONE NONE Sciences Inc Idenix COM 45166R204 12,850 1,250,000 SH DEFINED 3 1,250,000 NONE NONE Pharmaceuticals Inc Immunogen Inc COM 45253H101 61,374 3,666,300 SH DEFINED 3 3,666,300 NONE NONE Incyte Corp COM 45337C102 94,716 4,172,504 SH DEFINED 3 4,172,504 NONE NONE Isis COM 464330109 88,426 7,368,800 SH DEFINED 3 7,368,800 NONE NONE Pharmaceuticals Inc Onyx COM 683399109 23,689 356,500 SH DEFINED 2 356,500 NONE NONE Pharmaceuticals Inc Optimer COM 68401H104 22,830 1,476,700 SH DEFINED 3 1,476,700 NONE NONE Pharmaceuticals Inc The Medicines COM 584688105 36,209 1,578,417 SH DEFINED 2 1,578,417 NONE NONE Company Theravance Inc COM 88338T104 18,737 843,244 SH DEFINED 3 843,244 NONE NONE Vertex COM 92532F100 130,176 2,327,900 SH DEFINED 3 2,327,900 NONE NONE Pharmaceuticals Inc